EC approves AstraZeneca's diabetes combo Qtern

AstraZeneca plc (LSE:AZN; NYSE:AZN) said the European Commission approved Qtern saxagliptin/dapagliflozin to improve glycemic control in adults with Type II diabetes for whom metformin and/or sulfonylurea, plus either Qtern component alone, do not provide adequate control. It is also indicated for patients already receiving a free combination of Qtern's components.

AZ said it was the first EU approval for a product combining inhibitors of sodium-glucose cotransporter 2 ( SGLT2) and dipeptidyl peptidase-4 ( DPP-4; CD26). ...